Jazz Stock Hits New 52-Week High (JAZZ)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

NEW YORK ( TheStreet) -- Jazz Pharmaceuticals (Nasdaq: JAZZ) hit a new 52-week high Tuesday as it is currently trading at $57.31, above its previous 52-week high of $56.25 with 621,288 shares traded as of 10:05 a.m. ET. Average volume has been 692,800 shares over the past 30 days.

Jazz has a market cap of $2.77 billion and is part of the health care sector and drugs industry. Shares are up 43.1% year to date as of the close of trading on Monday.

Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, focuses on the identification, development, and commercialization of pharmaceutical products to meet unmet medical needs. The company has a P/E ratio of 20.1, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 17.7.

  • ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.

TheStreet Ratings rates Jazz as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. You can view the full Jazz Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free download now.
null

If you liked this article you might like

Acorda Shares Down on FDA's 'Refusal to File' Letter - Biotech Movers

Biotech Movers: Jazz Shares Lower Amid Notes Offering

Medivation Founder Takes Helm at Axovant, Shares Spike

Trevena, Synergy Lead Biotech Movers

Biotech Premarket Movers: ChemoCentryx, Jazz, Ionis, Zogenix